Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
about
A comparison of the aldosterone-blocking agents eplerenone and spironolactoneMineralocorticoid receptor antagonists and endothelial function30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.Hirsutism and the effectiveness of spironolactone in its management.Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function.Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis inductionEplerenone: a selective aldosterone receptor antagonist for patients with heart failure.Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort studySPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional StimuliMineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.Eplerenone for the treatment of cardiovascular disorders.Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.Antiandrogen therapy in dermatology.Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.Aldosterone-receptor antagonism and end-stage renal disease.The effect of spironolactone on experimental periodontitis in rats.Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression.Sexual Reassignment Fails to Prevent Kennedy's Disease.A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.Androgens and Therapeutic Aspects of Antiandrogens in WomenLong-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series
P2860
Q28276162-1BDF32FD-FA3B-4E62-8C9D-042DF0C92C76Q28645984-4F1B5534-1E23-47A5-99A3-A9E32823374BQ33846431-7F14D4E1-2663-4B64-9842-DF2D06DEC9FDQ34338540-6DEF38CC-B396-482C-B16E-AF048E13B801Q34425422-262EE21A-CE0B-440E-977A-4A49ABD25B54Q34518160-339884DE-3AEE-48FB-A90B-944D6666B9AFQ34542518-40FC5F70-64A4-4204-A63E-4AEAF4A55581Q35100840-E0A24A2C-3D75-4899-B92A-0CACF81E4238Q35980228-140AC6E2-33B7-4B63-A99B-9F7042FE1B59Q36094069-0CBF7E6A-2D59-4C1B-A62D-0F712972B4B0Q36419719-0A193465-88CE-4DE2-AF73-22F7A37F5FB3Q37299365-7CEE7FB1-3827-43AE-A0CE-01E0110FC68EQ37889518-5E26434D-3097-4AA5-91A6-BA62F7E66D29Q37897992-4A9FDE5F-DEE4-41FC-BF72-3D81FB908EA9Q38036328-8D0C556B-CA1A-4437-A4EE-ADA2E74D213CQ38177168-F506036D-398B-4197-B38A-252940637C7CQ38182029-E2453397-9311-43B3-AEB0-FEE62FCCF7C7Q41208689-E9DE74AF-8FF9-47F2-A406-7F7816BB3641Q42799853-8280C303-9864-40EF-807B-E44539EA66B4Q44060428-EE86E010-4CBD-4545-9D1F-5ABB56D615A6Q44903644-12C54BA2-B271-4DD3-AC3C-DC8F2504FDE5Q46457429-3C7EBDF9-CBCC-407D-B097-8327236CEEC2Q46628598-F7CE5410-19C8-4670-80D8-799FF243171BQ46984007-A7EC3478-2E6E-4A9C-AB3D-6100F8882853Q47944992-42D7427E-8FFC-4154-8B0F-5BE69369A79CQ51135561-5B74E808-D574-4D5C-B591-E87A5E697CA8Q53100119-4C0DFF97-E7CF-411E-8063-3B9C8B6D7D29Q55954238-C014FCBD-C4DC-42E0-8F9B-62C90B9CDEB4Q56429454-8C88E943-AD2C-489E-8AFF-D3B0F5EF523D
P2860
Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
description
1989 nî lūn-bûn
@nan
1989 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@ast
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@en
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@nl
type
label
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@ast
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@en
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@nl
prefLabel
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@ast
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@en
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@nl
P2093
P2860
P1476
Spironolactone metabolism: ste ...... sulfur-containing metabolites.
@en
P2093
Boreham DR
Gardiner P
P2860
P304
P356
10.1002/J.1552-4604.1989.TB03339.X
P577
1989-04-01T00:00:00Z